Revenue segments as reported by the company.

Net revenue, before excise taxes

Excise taxes

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Sales and marketing

Research and development

General and administrative

Restructuring costs

Share-based payments

Depreciation and amortization

Impairment loss on goodwill and indefinite-lived intangible assets

Impairment loss on long-lived assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cronos Group

Cronos Group, Inc. engages in the production and distribution of cannabis. Its brands include PEACE NATURALS, COVE, Spinach, Lord Jones, and PEACE+. The company was founded by Lorne Michael Gertner and Paul Rosen on August 21, 2012 and is headquartered in Toronto, Canada.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cronos Group, Inc. engages in the production and distribution of cannabis. I It operates through the Canada and Israel segments. The company was founded on August 21, 2012 and is headquartered in Toronto, Canada.

Aurora Cannabis

Canopy Growth

Tilray Brands

Cannabis stocks have had little issue raising capital. But they're also spending their money at a rapid pace.

Marijuana's "Big Four" Are Burning Through Cash at an Alarming Rate

After a parabolic rally in 2018, the cannabis sector came has come back down to earth in 2019.

Cannabis Stocks Show Signs Of Life As Aurora, Canopy, Others Move Higher

Cronos was once hailed as the best performing marijuana stock of all time, but how much can the pot firm grow from here?

Is Cronos Group Ready to Make a Comeback?

CRON stock  is off 50% since February, partly because investors see it like other, larger cannabis companies. Here's why Cronos Group stand's out.

Why Cronos Group Stock Stands Out in a Sea of Cannabis Sameness

The company puts a bow made of hemp on its $300 million CBD beauty products buy.

Cronos Group Closes Lord Jones Acquisition

HEXO Corp

Innovative Industrial Properties

Scotts Miracle-Gro

Each of these seven marijuana stocks can teach a valuable lesson into how to use technical analysis to identify important levels.

7 Marijuana Stocks With Critical Levels to Watch

CRON stock could continue to show strong revenue growth, making this dip a great buying opportunity in Cronos.
The post Strong Fundamentals Make Cronos Stock a Value Play  appeared first on InvestorPlace.

Strong Fundamentals Make Cronos Stock a Value Play 

For now, Cronos Group stock remains an extremely pricey marijuana play, despite its recent sharp losses. But in the long term, its backer Altria may mold and shape CRON into a cannabis version of itself.

Expect the Transformation of Cronos Group to Change CRON Stock

Cronos Group stock may not be attractive to institutions with ESG concerns. That is because its deal with Altria makes it a sin stock.

Cronos Group’s Deal with Altria Presents ESG Concerns for CRON Stock

Cronos Group Inc. shares CRON, -1.04% CRON, -1.16% fell 1% Tuesday, after Cowen cut its stock price target to C$17 ($13) from C$21, and said the company has not outlined its path to profitability in Canada and does not have the same scale as rivals Canopy Growth Corp.

Cronos stock falls after Cowen cuts price target, seeks outline of path to profitability in Canada

Aphria

GW Pharmaceuticals

You could rightly say that these five pot stocks are swimming with green.

5 of the Most Cash-Rich Cannabis Stocks

Cannabis stocks have declined significantly over the last 3 months.

Addressing Cannabis Stock Declines - Canopy Growth And Cronos

There are a ton of pot stocks out there, but only four of them have a realistic opportunity to strike gold in the long run.

The Only 4 Pot Stocks Worth Considering Long Term

Cronos stock is fundamentally undervalued. But the technicals and optics are broken.

Stay Away From Cronos Stock Until Support Arrives

Is this a warning that pot stock investors should heed?

Hedge Funds Absolutely Dumped Marijuana's "Big Three" in the Second Quarter

Cannabis stocks are contending with growing pains, and they aren't going to disappear overnight.

Canadian Marijuana Sales Hit a New High in June, but This Doesn't Tell the Full Story

Altria invested big in Cronos but the stock faded in the months that followed. With all that cash on hand, CRON stock is ready to grow.

Dumping Cronos Group Stock Is a Big Mistake

CRON stock has been popular because Cronos hasn't been on a rampant acquisition spree. But, that could be about to change.

Looming Goodwill Growth Makes CRON Stock Tough to Handicap

Although Cronos Group stock is backed by some positive fundamental drivers, the inability for the company -- or the sector as a whole -- to actualize some of this potential has scared off investors.
The post Here’s Why Cronos Stock Is Heading To $9 Per Share appeared first on InvestorPlace.

Here’s Why Cronos Stock Is Heading To $9 Per Share

TORONTO, Aug.  26, 2019  (GLOBE NEWSWIRE) -- Cronos Group Inc. (“Cronos Group” or the “Company”) (TSX: CRON) (Nasdaq: CRON), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and Chief Executive Officer of Cronos Group, will speak at Barclays Global Consumer Staples Conference at 10:30 a.m. ET in Boston, MA.

Cronos Group Inc. CEO, Mike Gorenstein, to Present at Barclays 2019 Global Consumer Staples Conference

CannTrust Holdings

Curaleaf Holdings, Inc.

Here's why marijuana stock market caps have gone up in smoke.

These 10 Pot Stocks Have Lost Nearly $21 Billion in Aggregate Value in 4 Months

TORONTO, Aug.  23, 2019  (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) has entered into a credit agreement (the “Credit Agreement”), as administrative agent and lender, with Cronos Growing Company Inc. (“Cronos GrowCo” or “GrowCo”), as borrower, in respect of a $100 million secured non-revolving term loan credit facility (the “Credit Facility”).

Cronos Group Inc. Enters into Credit Agreement with Cronos Growing Company Inc.

CRON stock just released its second-quarter earnings and the price of CRON stock has trended lower since then.
The post What Investors Should Know From Cronos Stock’s Earnings Release appeared first on InvestorPlace.

What Investors Should Know From Cronos Stock’s Earnings Release

Despite plunging valuations, these well-known marijuana stocks are worth avoiding.

3 Popular Pot Stocks At or Near Their 2019 Lows That Still Aren't Worth Buying

Hint: Most are years away from delivering consistent profits. But there's one notable exception.

News for Cronos Group Stock (CRON)